Magnesium Sulfate to Prevent Perioperative Atrial Fibrillation in Cardiac Surgery: A Randomized Clinical Trial
Abstract
Objectives: To determine whether perioperative IV magnesium sulfate infusion, targeting serum magnesium concentrations of 1.5–2.0 mmol/L, reduces the incidence of postoperative atrial fibrillation (POAF) in patients undergoing cardiac surgery. Design: Double-blind, randomized, placebo-controlled, single-center clinical trial with interim analysis for futility. Setting: HagaZiekenhuis, The Hague, The Netherlands (February 2022–November 2023). Patients: Adult patients undergoing coronary artery bypass grafting and/or valvular surgery without prior atrial arrhythmias or severe renal dysfunction. Interventions: Continuous IV infusion of magnesium sulfate (3 mmol/hr, with bolus if [baseline] magnesium < 1.0 mmol/L) or placebo (Ringer’s lactate), initiated after induction of anesthesia and continued until ICU discharge. Measurements and Main Results: A total of 265 patients underwent randomization before the trial was stopped at interim analysis for futility. Magnesium supplementation achieved clear separation in serum magnesium concentrations between groups. POAF occurred in 50 of 132 patients (37.9%) in the magnesium group and 38 of 133 patients (28.6%) in the placebo group (relative risk, 1.29; 95% CI, 0.92–1.80). No subgroup demonstrated benefit. Time-to-event and day-by-day analyses showed no early reduction in POAF with magnesium. Vasopressor use was more frequent in the magnesium group, although differences were not statistically significant. No safety signal was…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 265 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.